Valneva SE (VALN) Long-Term Investments (2020 - 2022)

Valneva SE (VALN) posted Long-Term Investments of $2.4 million for Q1 2022, down 1.89% sequentially from $2.4 million in Q4 2021.

Valneva SE (VALN) Long-Term Investments (2020 - 2022) Analysis & Trends

Valneva SE has reported Long-Term Investments for 3 years, with the latest figure at $2.4 million in Q1 2022.

Quarterly Long-Term Investments changed N/A year-over-year to $2.4 million in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $2.4 million (changed N/A YoY) and the FY2021 annual result came in at $2.5 million, up 3.35% from the prior year.
Long-Term Investments declined to $2.4 million in Q1 2022 per VALN's latest filing, from $2.4 million in the prior quarter.
Over five years, Long-Term Investments peaked at $2.5 million in Q4 2020 and troughed at $2.4 million in Q1 2022.
A 3-year average of $2.5 million and a median of $2.4 million in 2021 frame the typical range for Long-Term Investments.
The widest YoY moves for Long-Term Investments: up 4.32% in 2021, down 4.32% in 2021.
Over 3 years, Long-Term Investments stood at $2.5 million in 2020, then fell by 4.32% to $2.4 million in 2021, then fell by 1.89% to $2.4 million in 2022.
According to Business Quant data, Long-Term Investments over the past three periods registered $2.4 million, $2.4 million, and $2.5 million for Q1 2022, Q4 2021, and Q4 2020 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	5.79 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	9.83 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	372.10 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	22.17 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Valneva SE	618.67 Mn	477.41 Mn	1.86 Mn	-

Download Data